California Public Employees Retirement System raised its holdings in shares of Heska Corp (NASDAQ:HSKA) by 18.7% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,475 shares of the medical research company’s stock after buying an additional 2,914 shares during the period. California Public Employees Retirement System owned about 0.20% of Heska worth $1,721,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the business. Mutual of America Capital Management LLC raised its stake in Heska by 34.9% during the second quarter. Mutual of America Capital Management LLC now owns 410 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 106 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Heska by 223.9% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,170 shares of the medical research company’s stock valued at $120,000 after acquiring an additional 1,500 shares during the period. State of Tennessee Treasury Department raised its stake in shares of Heska by 11.5% in the first quarter. State of Tennessee Treasury Department now owns 2,377 shares of the medical research company’s stock valued at $131,000 after acquiring an additional 245 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Heska by 78.1% in the first quarter. BNP Paribas Arbitrage SA now owns 2,804 shares of the medical research company’s stock valued at $155,000 after acquiring an additional 1,230 shares during the period. Finally, Louisiana State Employees Retirement System purchased a new stake in shares of Heska in the second quarter valued at $218,000. 96.19% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on the stock. Alliance Global Partners increased their target price on shares of Heska from $90.00 to $116.50 and gave the company a “buy” rating in a research note on Wednesday, August 5th. BidaskClub raised shares of Heska from a “sell” rating to a “hold” rating in a research note on Saturday, September 12th. ValuEngine downgraded shares of Heska from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Zacks Investment Research downgraded shares of Heska from a “buy” rating to a “hold” rating in a research note on Tuesday, June 30th. Finally, Piper Sandler raised shares of Heska from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $87.00 to $110.00 in a research note on Wednesday, August 5th. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Heska presently has a consensus rating of “Hold” and an average target price of $89.92.

HSKA stock opened at $98.09 on Thursday. The firm has a 50 day moving average of $101.12 and a 200 day moving average of $84.98. The stock has a market capitalization of $926.36 million, a PE ratio of -58.04 and a beta of 1.71. The company has a quick ratio of 3.58, a current ratio of 4.82 and a debt-to-equity ratio of 0.18. Heska Corp has a 52 week low of $50.00 and a 52 week high of $110.90.

Heska (NASDAQ:HSKA) last released its earnings results on Tuesday, August 4th. The medical research company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.29). Heska had a negative return on equity of 1.57% and a negative net margin of 9.57%. The company had revenue of $45.71 million during the quarter, compared to analyst estimates of $41.94 million. On average, equities research analysts expect that Heska Corp will post -0.59 earnings per share for the current year.

In other news, COO Nancy Wisnewski sold 1,050 shares of Heska stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $103.87, for a total transaction of $109,063.50. Following the completion of the transaction, the chief operating officer now directly owns 49,124 shares of the company’s stock, valued at approximately $5,102,509.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kevin S. Wilson sold 9,176 shares of the business’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $107.13, for a total transaction of $983,024.88. Following the completion of the sale, the chief executive officer now directly owns 72,955 shares of the company’s stock, valued at approximately $7,815,669.15. The disclosure for this sale can be found here. 11.70% of the stock is owned by insiders.

About Heska

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.

See Also: What is a front-end load?

Want to see what other hedge funds are holding HSKA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heska Corp (NASDAQ:HSKA).

Institutional Ownership by Quarter for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.